AgeX Therapeutics, Inc. (AGE)
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States.
The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease.
Its lead drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550, a gene delivery technology.
The company has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases.
AgeX Therapeutics, Inc. was incorporated in 2017 and is based in Alameda, California.
|IPO Date||Nov 29, 2018|
1101 Marina Village Parkway
Alameda, California 94501
|Phone||510 671 8370|
|Fiscal Year End||December|
|Dr. Michael D. West Ph.D.||Founder, President, Chief Executive Officer and Director|
|Eun-Jae Park CPA||Chief Financial Officer|
|Dr. Nafees Naseer Malik M.D.||Chief Operating Officer|
|Dr. Ivan Labat||Chief Information Officer|
Latest SEC Filings
|Nov 25, 2022||8-K||Current Report|
|Nov 10, 2022||8-K||Current Report|
|Nov 10, 2022||10-Q||Quarterly Report|
|Nov 2, 2022||DEFA14A||Additional definitive proxy soliciting materials and Rule 14(a)(12) material|
|Nov 2, 2022||DEF 14A||Other definitive proxy statements|
|Oct 25, 2022||SC 13D/A||[Amend] General statement of acquisition of beneficial ownership|
|Oct 21, 2022||8-K||Current Report|
|Oct 5, 2022||PRER14A||Filing|
|Sep 16, 2022||PRE 14A||Other preliminary proxy statements|
|Aug 23, 2022||SC 13D/A||[Amend] General statement of acquisition of beneficial ownership|